vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $24.72 and traded as high as $29.01. vTv Therapeutics shares last traded at $29.01, with a volume of 8,889 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com cut vTv Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, May 13th.
Get Our Latest Analysis on vTv Therapeutics
vTv Therapeutics Price Performance
The stock has a 50 day simple moving average of $24.98 and a 200-day simple moving average of $15.86. The firm has a market cap of $87.32 million, a PE ratio of -3.28 and a beta of 0.52.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($1.67) earnings per share for the quarter.
Hedge Funds Weigh In On vTv Therapeutics
An institutional investor recently bought a new position in vTv Therapeutics stock. Baker BROS. Advisors LP purchased a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 97,314 shares of the biotechnology company's stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned about 3.23% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
